Ditchcarbon
  • Customers
  1. Organizations
  2. CRISPR Therapeutics AG
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 10 days ago

CRISPR Therapeutics AG

Company website

CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA. With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions. Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.

DitchCarbon Score

How does CRISPR Therapeutics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

28

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

CRISPR Therapeutics AG's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.

53%

Let us know if this data was useful to you

CRISPR Therapeutics AG's reported carbon emissions

CRISPR Therapeutics AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). Without any climate pledges or reduction initiatives, CRISPR Therapeutics AG's current stance on carbon emissions remains unclear. As there is no inherited emissions data from a parent or related organization, all information is based solely on the company's own disclosures. In the context of the biotechnology industry, it is essential for companies like CRISPR Therapeutics AG to develop and communicate clear climate commitments to align with global sustainability goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. CRISPR Therapeutics AG's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for CRISPR Therapeutics AG is in CH, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

CRISPR Therapeutics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Novartis International AG

CH
•
Real estate services (70)
Updated 13 days ago

Emmaus Life Sciences, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Incyte

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

PharmaEssentia USA Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Agios

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy